One of the things we’re finding is that severe hematologic toxicity in the treatment of [patients with] small cell [lung cancer] is much more common than most practitioners realize, and I can put myself in that same category when we started looking at it more concretely. Small cell [lung] cancer is [certainly] one of those […]
23Dec
Categories:
SC Lung Cancer
Comments Off on The Role of Trilaciclib in the Management of Chemotherapy-Induced Myelosuppression in SCLC

10Sep
Small-cell lung cancer (SCLC) accounts for nearly 15% of all lung cancer diagnoses in the United States. While treatment for the more common non-small-cell lung cancer (NSCLC) has improved over the past decade with the advent of new targeted therapies, SCLC remains difficult to treat. Lung cancer develops when cells in the lungs grow out […]
